Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.

Abstract

Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.

• Authors: Jonathan L Wright, Daniel W Lin, Puneet Dewan, R Bruce Montgomery
• Journal: International journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 12 Issue 11 Pg. 1012-3 (Nov 2005) ISSN: 0919-8172 [Print] Australia
• PMID: 16351664 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Prostate-Specific Antigen
• Paclitaxel

Topics

• Adenocarcinoma (pathology, therapy)
• Antineoplastic Agents, Phytogenic (administration & dosage, adverse effects)
• Bone Marrow Neoplasms (drug therapy, secondary)
• Bone Neoplasms (drug therapy, secondary)
• Hematuria (etiology)
• Humans
• Hydronephrosis (etiology)
• Liver Neoplasms (drug therapy, secondary)
• Male
• Middle Aged
• Paclitaxel (administration & dosage, adverse effects)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (pathology, therapy)
• Renal Dialysis
• Renal Insufficiency (etiology, therapy)
• Tumor Lysis Syndrome (etiology)